MCID: CRN030
MIFTS: 52

Coronary Stenosis

Categories: Cardiovascular diseases

Aliases & Classifications for Coronary Stenosis

MalaCards integrated aliases for Coronary Stenosis:

Name: Coronary Stenosis 12 56 45 15 17 74
Coronary Artery Stenosis 12 15

Classifications:



External Ids:

Disease Ontology 12 DOID:4248
MeSH 45 D023921
NCIt 51 C80427
UMLS 74 C0242231

Summaries for Coronary Stenosis

MalaCards based summary : Coronary Stenosis, also known as coronary artery stenosis, is related to cardiogenic shock and kawasaki disease, and has symptoms including angina pectoris An important gene associated with Coronary Stenosis is APOA1 (Apolipoprotein A1), and among its related pathways/superpathways are Lipoprotein metabolism and Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers. The drugs Aspirin and Clopidogrel have been mentioned in the context of this disorder. Affiliated tissues include heart, testes and endothelial, and related phenotypes are Decreased free cholesterol and cardiovascular system

Related Diseases for Coronary Stenosis

Diseases related to Coronary Stenosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 245)
# Related Disease Score Top Affiliating Genes
1 cardiogenic shock 30.3 IL6 NPPB PIK3C2A
2 kawasaki disease 30.2 ALB CRP IL6 NPPB
3 takayasu arteritis 30.1 CRP IL6 PON1 VWF
4 angina pectoris 30.0 ACE CRP IL6 NPPB PIK3C2A
5 pericarditis 29.8 CRP IL6 NPPB
6 left bundle branch hemiblock 29.7 ACE NPPB TNNI3
7 end stage renal failure 29.7 ACE ALB APOB CRP IL6
8 aortic valve disease 2 29.5 ACE CRP NPPB VWF
9 atrial fibrillation 29.4 ACE CRP NPPB VWF
10 kidney disease 29.3 ACE ALB APOE CRP IL6 NPPB
11 cardiac arrest 29.2 ACE ALB NPPB PIK3C2A
12 ischemic heart disease 29.1 ACE APOA1 APOB APOE CRP IL6
13 myocarditis 29.1 ICAM1 IL6 NPPB TNNI3
14 pulmonary embolism 29.0 ALB CRP NPPB SERPINE1 TNNI3 VWF
15 hypercholesterolemia, familial 28.9 ACE APOA1 APOB APOE CETP CRP
16 stroke, ischemic 28.9 ACE APOB APOE CRP PON1 SERPINE1
17 coronary artery anomaly 28.7 ACE APOA1 APOB CETP CRP NPPB
18 acute myocardial infarction 28.7 ACE APOA1 APOB CRP NPPB PIK3C2A
19 chronic kidney failure 28.5 ACE ALB APOB CRP ICAM1 IL6
20 atherosclerosis susceptibility 28.4 APOA1 APOB APOE CETP CRP ICAM1
21 diabetes mellitus 28.3 ACE ALB APOA1 APOB CRP IL6
22 coronary heart disease 1 28.2 ACE APOA1 APOB APOE CETP CRP
23 arteriosclerosis 28.1 ACE APOA1 APOB APOE CRP ICAM1
24 cerebrovascular disease 27.9 ACE APOA1 APOB APOE CRP ICAM1
25 diabetes mellitus, noninsulin-dependent 27.9 ACE ALB APOA1 APOB APOE CETP
26 arteries, anomalies of 27.4 ACE ALB APOA1 APOB APOE CETP
27 myocardial infarction 26.9 ACE ALB APOA1 APOB APOE CETP
28 heart disease 26.6 ACE ALB APOA1 APOB APOE CRP
29 ischemia 10.5
30 cold agglutinin disease 10.4 CRP IL6
31 moderate and severe traumatic brain injury 10.4 ACE APOE
32 cryopyrin-associated periodic syndrome 10.4 CRP IL6
33 acute transverse myelitis 10.4 APOA1 IL6
34 acute cholangitis 10.4 CRP IL6
35 loeffler syndrome 10.3 ACE ALB
36 gastrointestinal tuberculosis 10.3 ALB CRP
37 hepatic lipase deficiency 10.3 APOA1 APOE
38 generalized atherosclerosis 10.3 ACE APOE CRP
39 abdominal tuberculosis 10.3 ALB CRP
40 aortic disease 10.3 APOE CRP IL6
41 uremic pruritus 10.3 CRP IL6
42 cerebral atherosclerosis 10.3 ACE APOA1 APOE
43 pyuria 10.3 ALB CRP
44 vibrio vulnificus infection 10.3 IL6 PIK3C2A
45 carotid stenosis 10.3 ACE APOE CRP
46 meningitis 10.3 ALB CRP IL6
47 xanthoma disseminatum 10.3 APOB APOE
48 acute cystitis 10.2 ALB CRP IL6
49 rheumatic myocarditis 10.2 CRP TNNI3
50 anterolateral myocardial infarction 10.2 ACE NPPB

Graphical network of the top 20 diseases related to Coronary Stenosis:



Diseases related to Coronary Stenosis

Symptoms & Phenotypes for Coronary Stenosis

UMLS symptoms related to Coronary Stenosis:


angina pectoris

GenomeRNAi Phenotypes related to Coronary Stenosis according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased free cholesterol GR00340-A-2 8.92 APOA1 APOB APOE CETP

MGI Mouse Phenotypes related to Coronary Stenosis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.18 ACE APOA1 APOB APOE CRP ICAM1
2 homeostasis/metabolism MP:0005376 10.18 ACE ALB APOA1 APOB APOE CPB2
3 immune system MP:0005387 10.02 ACE APOB APOE CPB2 CRP ICAM1
4 mortality/aging MP:0010768 9.9 ACE ALB APOB APOE CPB2 ICAM1
5 liver/biliary system MP:0005370 9.8 ACE ALB APOA1 APOB APOE IL6
6 neoplasm MP:0002006 9.43 ACE ALB CPB2 ICAM1 IL6 SERPINE1
7 renal/urinary system MP:0005367 9.17 ACE ALB APOE CPB2 IL6 PIK3C2A

Drugs & Therapeutics for Coronary Stenosis

Drugs for Coronary Stenosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 216)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Aspirin Approved, Vet_approved Phase 4,Phase 3,Not Applicable 50-78-2 2244
2
Clopidogrel Approved Phase 4,Phase 3,Not Applicable 120202-66-6, 113665-84-2 60606
3
Everolimus Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 159351-69-6 6442177 70789204
4
Cilostazol Approved, Investigational Phase 4,Phase 3,Not Applicable 73963-72-1 2754
5
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 53123-88-9 46835353 6436030 5284616
6
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 22916-47-8 4189
7
Azathioprine Approved Phase 4 446-86-6 2265
8
Mycophenolic acid Approved Phase 4 24280-93-1 446541
9
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 11128-99-7, 4474-91-3 172198 65143
10
Olmesartan Approved, Investigational Phase 4 144689-24-7, 144689-63-4 130881 158781
11
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 33069-62-4 36314
12
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
13
Glucagon Approved Phase 4,Not Applicable 16941-32-5
14
Chlorhexidine Approved, Vet_approved Phase 4,Phase 2,Phase 3,Not Applicable 55-56-1 2713 9552079
15
Adenosine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 58-61-7 60961
16
Pioglitazone Approved, Investigational Phase 4,Phase 3 111025-46-8 4829
17
Regadenoson Approved, Investigational Phase 4,Phase 2,Not Applicable 313348-27-5 219024
18
Cobalt Approved, Experimental Phase 4,Phase 2,Phase 3,Not Applicable 7440-48-4 104729
19
Chromium Approved Phase 4,Phase 2,Phase 3,Not Applicable 7440-47-3 27668
20
Isosorbide Dinitrate Approved, Investigational Phase 4,Not Applicable 87-33-2 6883
21
AT-101 Approved, Investigational Phase 4,Not Applicable 90141-22-3, 652-67-5 12597
22
Nitric Oxide Approved Phase 4 10102-43-9 145068
23
Liraglutide Approved Phase 4 204656-20-2 44147092
24
Iodine Approved, Investigational Phase 4,Not Applicable 7553-56-2 807
25
Ticagrelor Approved Phase 4 274693-27-5 9871419
26 Orange Approved Phase 4
27
Acetylcarnitine Approved, Investigational Phase 4 3040-38-8 7045767
28
Quinapril Approved, Investigational Phase 4 85441-61-8 54892
29
Probucol Approved, Investigational Phase 4 23288-49-5 4912
30
Diltiazem Approved, Investigational Phase 4,Not Applicable 42399-41-7 39186
31
Edoxaban Approved Phase 4 480449-70-5
32
Calcium Approved, Nutraceutical Phase 4,Phase 3,Phase 2,Not Applicable 7440-70-2 271
33
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Not Applicable 59-30-3 6037
34
Serine Approved, Nutraceutical Phase 4,Phase 2,Not Applicable 56-45-1 5951
35
Imidacloprid Vet_approved Phase 4 105827-78-9 86418
36
Sarpogrelate Investigational Phase 4 125926-17-2 5160
37 Peripheral Nervous System Agents Phase 4,Phase 3,Not Applicable
38 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Not Applicable
39 Fibrinolytic Agents Phase 4,Phase 3,Phase 1,Not Applicable
40 Cyclooxygenase Inhibitors Phase 4,Phase 3,Not Applicable
41 Anti-Inflammatory Agents, Non-Steroidal Phase 4,Phase 3,Not Applicable
42 Antipyretics Phase 4,Phase 3,Not Applicable
43 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Not Applicable
44 Purinergic P2 Receptor Antagonists Phase 4,Phase 3,Not Applicable
45 Analgesics Phase 4,Phase 3,Not Applicable
46 Platelet Aggregation Inhibitors Phase 4,Phase 3,Phase 2,Not Applicable
47 Purinergic P2Y Receptor Antagonists Phase 4,Phase 3,Not Applicable
48 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Not Applicable
49 Analgesics, Non-Narcotic Phase 4,Phase 3,Not Applicable
50 Protective Agents Phase 4,Phase 3,Not Applicable

Interventional clinical trials:

(show top 50) (show all 495)
# Name Status NCT ID Phase Drugs
1 Comparison of Fractional Flow Reserve and Intravascular Ultrasound Unknown status NCT01133015 Phase 4
2 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis- EXtended Antiplatelet Monotherapy (HOST-EXAM) Unknown status NCT02044250 Phase 4 Clopidogrel;Aspirin
3 Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - SAfety & EffectiveneSS of Drug-ElUting Stents & Anti-platelet REgimen Unknown status NCT01267734 Phase 4 Triple anti-platelet therapy (TAT);Double-dose clopidogrel anti-platelet therapy (DDAT)
4 Efficacy of Xience/Promus Versus Cypher in rEducing Late Loss After stENTing Unknown status NCT00698607 Phase 4 6-month clopidogrel therapy;12-month clopidogrel therapy
5 Study of Endothelial Dysfunction in Systemic Lupus and Its Role in Heart Disease Unknown status NCT00188188 Phase 4 quinipril
6 Study to Evaluate Effect of Everolimus in Progression of Graft Vascular Illness on Patients With Heart Transplant Unknown status NCT00695344 Phase 4 everolimus;azathioprine or mycophenolate mofetil
7 Diagnostic Performance of Noninvasive Fractional Flow Reserve From Computed Tomography Unknown status NCT01747317 Phase 4
8 Efficacy Study of Olmesartan Medoxomil on Coronary Atherosclerosis and Epicardial Adipose Tissue(EAT) Unknown status NCT02360956 Phase 4 Olmesartan medoxomil tablets;Antihypertensive medication (per doctor suggestion)
9 ESOS (Endoscopic Saphenous Harvesting With an Open CO2 System) Trial Unknown status NCT01121341 Phase 4
10 Study of the Paclitaxel-Coated Balloon Catheter in Bifurcated Coronary Lesions Unknown status NCT01278186 Phase 4
11 Effect of Combination of Non-sLip Element Balloon (NSE) and druG-coated bAlloon (DCB) for In-steNT Restenosis Lesions Unknown status NCT02300454 Phase 4
12 Effects of Celecoxib On Restenosis After Coronary Intervention and Evolution of Atherosclerosis Trial Unknown status NCT00500279 Phase 4 Celecoxib
13 SCRIPPS V: Intracoronary Brachytherapy for Recurrent Restenosis After Multiple Drug-Eluting Stents Unknown status NCT00714545 Phase 4
14 The Effect of Tongguan Capsule for MicroRNA Profiles in Coronary Heart Disease Patients Unknown status NCT02850627 Phase 4 Tongguan capsule;placebo capsule
15 A Clinical Trials of Quick-Acting Heart Reliever for Moderate Coronary Stenosis Completed NCT01513070 Phase 4 Quick-Acting Heart Reliever;Isosorbide Dinitrate;Placebo of Isosorbide Dinitrate;Aspirin Enteric-coated Tablets;Placebo of Quick-Acting Heart Reliever;Aspirin Enteric-coated Tablets
16 Physiologic Evaluation of Anomalous Right Coronary Artery Stenosis Completed NCT01133054 Phase 4
17 Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary Stenosis Completed NCT02602600 Phase 4 Liraglutide
18 Excel Drug-Eluting Stent Pilot Clinical Registry Completed NCT00385905 Phase 4
19 Contrast Enhancement on Coronary Computed Tomographic Angiography Completed NCT02462044 Phase 4 240 mg Iodine;300 mg Iodine;370 mg Iodine
20 Optical Coherence Tomography to Investigate FFR-Guided DEB-only Elective Coronary Angioplasty Completed NCT02120859 Phase 4
21 Kidney Damage in Patients With Normal eGFR Completed NCT01137786 Phase 4 Non ionic contrast media comparator;Non ionic contrast media comparator
22 Kidney Damage in Patients With Moderate Fall in eGFR Completed NCT01136876 Phase 4 Iopamidol;Iodixanol-320
23 Z-SEA-SIDE: Sirolimus Versus Everolimus Versus Zotarolimus-eluting Stent Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis Completed NCT01200693 Phase 4
24 SEA-SIDE: Sirolimus Versus Everolimus-eluting Stent Randomized Assessment in Bifurcated Lesions and Clinical SIgnificance of Residual siDE-branch Stenosis Completed NCT00697372 Phase 4
25 Vision II: Evaluation of GALILEO Intravascular Radiotherapy System Completed NCT00180583 Phase 4
26 The Effect of Pioglitazone on Neointima Volume and Inflammatory Markers Completed NCT00494559 Phase 4 Pioglitazone;Placebo
27 Women With Chest Pain and no Significant Coronary Artery Stenosis; A Study on Microvascular Resistance Completed NCT01582165 Phase 4 Rosuvastatin;Placebo.
28 Xenetix® 350: Comparative Assessment of Image Quality for Coronary CT Angiography Completed NCT01255722 Phase 4 iobitridol;iopromide;iomeprol
29 Healthy Endothelial Accelerated Lining Inhibits Neointimal Growth Completed NCT00349895 Phase 4
30 Cost-Effectiveness Study in the Reduction of Coronary Restenosis With Sirolimus-Eluting Stents Completed NCT00627900 Phase 4
31 Optical Coherence Tomography to Evaluate Ticagrelor and Clopidogrel Completed NCT02140801 Phase 4 Ticagrelor;Clopidogrel
32 Comparison of Zotarolimus-Eluting Stent vs Sirolimus-Eluting Stent for Diabetic Patients Completed NCT01186107 Phase 4
33 Comparison of Everolimus-Eluting Stent vs Sirolimus-Eluting Stent in Patients With DIABETES Mellitus Completed NCT00997763 Phase 4
34 Zotarolimus-Eluting Stent Versus Sirolimus-Eluting Stent and PacliTaxel-Eluting Stent for Coronary Lesions Completed NCT00418067 Phase 4
35 Study of Unprotected Left Main Stenting Versus Bypass Surgery (LE MANS Study) Completed NCT00375063 Phase 4
36 EXecutive RCT: Evaluating XIENCE V® in a Multi Vessel Disease Completed NCT00531011 Phase 4
37 Optical Coherence Tomography to Evaluate Paclitaxel-Eluting Balloons and Everolimus-Eluting Coronary Stents Completed NCT01056744 Phase 4
38 Sirolimus-Eluting Stent Versus Standard Stent in Diabetic Completed NCT00755443 Phase 4
39 Real Time Myocardial Perfusion Echocardiography for Coronary Allograft Vasculopathy Completed NCT02880137 Phase 4 Perflutren Lipid Microsphere
40 Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson Completed NCT01779869 Phase 4 Regadenoson
41 Effect of Ticagrelor on Fractional Flow Reserve Completed NCT02108808 Phase 4 Ticagrelor;Prasugrel or Clopidogrel
42 The Real-World Endeavor Resolute Versus XIENCE V Drug-Eluting Stent Study in Twente Completed NCT01066650 Phase 4
43 Austrian Multivessel Taxus-Stent Registry Completed NCT00738686 Phase 4
44 Sympathetic Heart Innervation in Patients With Tako-Tsubo Cardiomyopathy Completed NCT01524861 Phase 4 Placebo;alpha-lipoic acid;L-acetyl carnitine
45 QWISE - Study of Quinapril in Women With Chest Pain, Coronary Flow Reserve Limitations and Evidence of Myocardial Ischemia Completed NCT00150826 Phase 4 Quinapril;Placebo
46 Comparison of Hyperemic Efficacy Between Central and Peripheral Adenosine Infusion for Fractional Flow Reserve (FFR) Measurement Completed NCT01070420 Phase 4
47 Ontario Multidetector Computed Tomographic (MDCT) Coronary Angiography Study (OMCAS) Completed NCT00371891 Phase 4
48 DUrable Polymer-based STent CHallenge of Promus Element Versus ReSolute Integrity in an All Comers Population Completed NCT01331707 Phase 4
49 Optimal Stenting Strategy For True Bifurcation Lesions Completed NCT00693251 Phase 4
50 XIENCE V: SPIRIT WOMEN Sub-study Completed NCT01182428 Phase 4

Search NIH Clinical Center for Coronary Stenosis

Cochrane evidence based reviews: coronary stenosis

Genetic Tests for Coronary Stenosis

Anatomical Context for Coronary Stenosis

MalaCards organs/tissues related to Coronary Stenosis:

42
Heart, Testes, Endothelial, Brain, Kidney, Monocytes, Eye

Publications for Coronary Stenosis

Articles related to Coronary Stenosis:

(show top 50) (show all 1821)
# Title Authors Year
1
The relationship between radiation doses to coronary arteries and location of coronary stenosis requiring intervention in breast cancer survivors. ( 30845947 )
2019
2
Patients with Acute Ischemic Cerebrovascular Disease with Coronary Artery Stenosis Have More Diffused Cervicocephalic Atherosclerosis. ( 30726790 )
2019
3
Predicting asymptomatic coronary artery stenosis by aortic arch plaque in acute ischemic cerebrovascular disease: beyond the cervicocephalic atherosclerosis? ( 30829720 )
2019
4
Transcatheter Intervention for Treatment of Coronary Stenosis After Unroofing of the Anomalous Left Coronary Artery. ( 30343330 )
2019
5
Diagnostic performance of cCTA derived stenosis predictors to detect hemodynamic significant coronary stenosis. ( 30449338 )
2019
6
Coronary stenosis and left ventricular function - Major prognostic factors in patients with ischemic heart disease: Has something changed in the era of "precision medicine"? ( 30545618 )
2019
7
Current mechanisms of low graft flow and conduit choice for the right coronary artery based on the severity of native coronary stenosis and myocardial flow demand. ( 30737658 )
2019
8
Synchrotron radiation computed tomography assessment of calcified plaques and coronary stenosis with different slice thicknesses and beam energies on 3D printed coronary models. ( 30788242 )
2019
9
Expression pattern of miR-21, miR-25 and PTEN in peripheral blood mononuclear cells of patients with significant or insignificant coronary stenosis. ( 30849539 )
2019
10
The best predictor of ischemic coronary stenosis: subtended myocardial volume, machine learning-based FFRCT, or high-risk plaque features? ( 30903334 )
2019
11
Study on correlation between property of coronary artery lesion and degree of coronary artery stenosis of elderly patients with coronary heart disease. ( 30881430 )
2019
12
sSema4D levels are increased in coronary heart disease and associated with the extent of coronary artery stenosis. ( 30658102 )
2019
13
Association of Hemodynamic Severity With Plaque Vulnerability and Complexity of Coronary Artery Stenosis: A Combined Optical Coherence Tomography and Fractional Flow Reserve Study. ( 30660534 )
2019
14
Comparison of clinical outcomes following percutaneous coronary intervention versus optimal medical therapy based on gray-zone fractional flow reserve in stable angina patients with intermediate coronary artery stenosis (COMFORTABLE prospective study): Study protocol for a multicenter randomized controlled trial. ( 30691507 )
2019
15
Biostial iatrogenic coronary artery stenosis: a rare complication of aortic valve surgery successfully treated with percutaneous coronary stenting. ( 30698782 )
2019
16
Response by Alqarqaz et al to Letter Regarding Article, "Effects of Impella on Coronary Perfusion in Patients With Critical Coronary Artery Stenosis". ( 30722687 )
2019
17
Letter by Kern et al Regarding Article, "Effects of Impella on Coronary Perfusion in Patients With Critical Coronary Artery Stenosis". ( 30722690 )
2019
18
Spontaneous Coronary Artery Dissection Masquerading as Coronary Artery Stenosis in a Young Patient. ( 30723187 )
2019
19
Association of coronary artery Doppler-echocardiography diastolic-systolic velocity ratio at rest with obstructive coronary artery stenosis on the left main or left anterior descending coronary artery. ( 30739803 )
2019
20
Effect of Cilostazol, a Phosphodiesterase-3 Inhibitor, on Coronary Artery Stenosis and Plaque Characteristics in Patients with Type 2 Diabetes (ESCAPE Study). ( 30761717 )
2019
21
Effects of metformin therapy on COronary endothelial DYsfunction in prediabetic patients With stable angina and Non Obstructive Coronary Artery Stenosis: The CODYCE Multicenter Prospective Study. ( 30796109 )
2019
22
Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting in Unprotected Left Main Coronary Artery Stenosis. ( 30797504 )
2019
23
Successful intravascular lithotripsy for severely calcified left anterior descending coronary artery stenosis. ( 30845133 )
2019
24
Diagnostic Performance of QFR for the Evaluation of Intermediate Coronary Artery Stenosis Confirmed by Fractional Flow Reserve. ( 30916126 )
2019
25
Cardiogoniometry Compared to Fractional Flow Reserve at Identifying Physiologically Significant Coronary Stenosis: The CARDIOFLOW Study. ( 29651685 )
2018
26
Quantitative baseline CT plaque characterization of unrevascularized non-culprit intermediate coronary stenosis predicts lesion volume progression and long-term prognosis: A serial CT follow-up study. ( 29548539 )
2018
27
Saline induced Pd/Pa ratio predicts functional significance of coronary stenosis assessed using fractional flow reserve. ( 29688181 )
2018
28
Delayed flow-mediated vasodilation and critical coronary stenosis. ( 29550752 )
2018
29
CT morphological index provides incremental value to machine learning based CT-FFR for predicting hemodynamically significant coronary stenosis. ( 29885695 )
2018
30
Deferred vs. performed revascularization for coronary stenosis with grey-zone fractional flow reserve values: data from the IRIS-FFR registry. ( 29529177 )
2018
31
The characteristics of coronary stenosis in 11,267 patients from Southwest China: a retrospective study. ( 29019045 )
2018
32
Resting Pd/Pa and haemodynamic relevance of coronary stenosis as evaluated by fractional flow reserve. ( 29028737 )
2018
33
Effects of incretin treatment on cardiovascular outcomes in diabetic STEMI-patients with culprit obstructive and multivessel non obstructive-coronary-stenosis. ( 29308090 )
2018
34
Evolving Routine Standards in InvasiveA Hemodynamic Assessment of Coronary Stenosis: TheA Nationwide Italian SICI-GISE Cross-Sectional ERIS Study. ( 29803695 )
2018
35
Diagnostic Concordance and Clinical Outcomes in Patients Undergoing Fractional Flow Reserve and Stress Echocardiography for the Assessment of Coronary Stenosis of Intermediate Severity. ( 29246509 )
2018
36
Fully quantitative pixel-wise analysis of cardiovascular magnetic resonance perfusion improves discrimination of dark rim artifact from perfusion defects associated with epicardial coronary stenosis. ( 29514708 )
2018
37
Combined Assessment of Stress Myocardial Perfusion Cardiovascular Magnetic Resonance and Flow Measurement in the Coronary Sinus Improves Prediction of Functionally Significant Coronary Stenosis Determined by Fractional Flow Reserve in Multivessel Disease. ( 29432130 )
2018
38
Computation of hemodynamics in eccentric coronary stenosis: A morphological parametric study. ( 29660973 )
2018
39
Invasive physiological indices to determine the functional significance of coronary stenosis. ( 29876502 )
2018
40
Fractional flow reserve-CT assessment of coronary stenosis. ( 29569282 )
2018
41
Calcification remodeling index assessed by cardiac CT predicts severe coronary stenosis in lesions with moderate to severe calcification. ( 28988831 )
2018
42
A new CFD based non-invasive method for functional diagnosis of coronary stenosis. ( 29566702 )
2018
43
Diagnostic accuracy of ASLA score (a novel CT angiographic index) and aggregate plaque volume in the assessment of functional significance of coronary stenosis. ( 29907444 )
2018
44
Fusion of Three-Dimensional Echocardiographic Regional Myocardial Strain with Cardiac Computed Tomography for Noninvasive Evaluation of the Hemodynamic Impact of Coronary Stenosis in Patients with Chest Pain. ( 29576220 )
2018
45
Beta 2-Microglobulin and the Severity of Coronary Stenosis in Patients With Acute Coronary Syndrome. ( 29573958 )
2018
46
Ascending Aortic Strain Analysis Using 2-Dimensional Speckle Tracking Echocardiography Improves the Diagnostics for Coronary Artery Stenosis in Patients With Suspected Stable Angina Pectoris. ( 29982229 )
2018
47
Exercise-induced Atrioventricular Block with Coronary Artery Stenosis that Appeared Five Years after Bypass Surgery. ( 29093419 )
2018
48
Development of a Porcine Model of Coronary Stenosis Using Fully Percutaneous Techniques Suitable For Performing Cardiac Computed Tomography, CT-Perfusion Imaging and Fractional Flow Reserve. ( 30054125 )
2018
49
Comparison of Computed Tomography derived Fractional Flow Reserve to invasive Fractional Flow Reserve in Diagnosis of Functional Coronary Stenosis: A Meta-Analysis. ( 30069020 )
2018
50
Fate of Grafts Bypassing Nonischemic Versus Ischemic Inducing Coronary Stenosis. ( 30075891 )
2018

Variations for Coronary Stenosis

Expression for Coronary Stenosis

Search GEO for disease gene expression data for Coronary Stenosis.

Pathways for Coronary Stenosis

Pathways related to Coronary Stenosis according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.3 ALB APOA1 APOB APOE CETP
2 11.78 ALB IL6 TNNI3
3 11.66 ALB APOA1 APOE TNNI3
4 11.61 ICAM1 IL6 SERPINE1
5
Show member pathways
11.56 ALB APOA1 APOB APOE CRP ICAM1
6
Show member pathways
11.53 APOA1 APOB APOE CETP
7
Show member pathways
11.27 ALB APOA1 APOB APOE
8 11.26 APOB ICAM1 IL6
9 11.07 APOA1 ICAM1 IL6
10 10.74 CRP IL6

GO Terms for Coronary Stenosis

Cellular components related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.93 ACE ALB APOA1 APOB APOE CETP
2 endoplasmic reticulum lumen GO:0005788 9.89 ALB APOA1 APOB APOE IL6
3 collagen-containing extracellular matrix GO:0062023 9.88 APOA1 APOE ICAM1 SERPINE1 VWF
4 blood microparticle GO:0072562 9.83 ALB APOA1 APOE PON1
5 extracellular region GO:0005576 9.77 ACE ALB APOA1 APOB APOE CETP
6 platelet alpha granule lumen GO:0031093 9.71 ALB SERPINE1 VWF
7 very-low-density lipoprotein particle GO:0034361 9.63 APOA1 APOB APOE
8 endocytic vesicle lumen GO:0071682 9.61 APOA1 APOB APOE
9 low-density lipoprotein particle GO:0034362 9.58 APOA1 APOB APOE
10 high-density lipoprotein particle GO:0034364 9.56 APOA1 APOE CETP PON1
11 spherical high-density lipoprotein particle GO:0034366 9.55 APOA1 PON1
12 chylomicron GO:0042627 9.54 APOA1 APOB APOE
13 discoidal high-density lipoprotein particle GO:0034365 9.51 APOA1 APOE
14 intermediate-density lipoprotein particle GO:0034363 9.5 APOA1 APOB APOE
15 extracellular space GO:0005615 9.44 ACE ALB APOA1 APOB APOE CETP

Biological processes related to Coronary Stenosis according to GeneCards Suite gene sharing:

(show all 43)
# Name GO ID Score Top Affiliating Genes
1 post-translational protein modification GO:0043687 9.98 ALB APOA1 APOB APOE IL6
2 receptor-mediated endocytosis GO:0006898 9.92 ALB APOA1 APOB APOE
3 lipid transport GO:0006869 9.88 APOA1 APOB APOE CETP
4 platelet degranulation GO:0002576 9.86 ALB APOA1 SERPINE1 VWF
5 steroid metabolic process GO:0008202 9.85 APOA1 APOB APOE CETP
6 cellular protein metabolic process GO:0044267 9.83 ALB APOA1 APOB APOE IL6
7 cholesterol homeostasis GO:0042632 9.78 APOA1 APOB APOE CETP
8 retinoid metabolic process GO:0001523 9.77 APOA1 APOB APOE
9 triglyceride homeostasis GO:0070328 9.74 APOA1 APOE CETP
10 cholesterol transport GO:0030301 9.71 APOA1 APOB CETP
11 triglyceride catabolic process GO:0019433 9.7 APOA1 APOB APOE
12 positive regulation of lipid biosynthetic process GO:0046889 9.69 APOA1 APOE
13 heart contraction GO:0060047 9.69 ACE TNNI3
14 cholesterol efflux GO:0033344 9.69 APOA1 APOB APOE
15 negative regulation of blood coagulation GO:0030195 9.68 APOE SERPINE1
16 positive regulation of cholesterol efflux GO:0010875 9.68 APOE PON1
17 regulation of blood vessel diameter GO:0097746 9.68 ACE NPPB
18 high-density lipoprotein particle assembly GO:0034380 9.68 APOA1 APOE
19 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.67 CETP CRP
20 phosphatidylcholine metabolic process GO:0046470 9.67 CETP PON1
21 phospholipid efflux GO:0033700 9.67 APOA1 APOE
22 lipoprotein metabolic process GO:0042157 9.67 APOA1 APOB APOE
23 high-density lipoprotein particle clearance GO:0034384 9.66 APOA1 APOE
24 negative regulation of fibrinolysis GO:0051918 9.66 CPB2 SERPINE1
25 phospholipid homeostasis GO:0055091 9.65 APOA1 CETP
26 negative regulation of lipid storage GO:0010888 9.65 CRP IL6
27 positive regulation of cholesterol esterification GO:0010873 9.65 APOA1 APOE
28 chylomicron remnant clearance GO:0034382 9.64 APOB APOE
29 neutrophil mediated immunity GO:0002446 9.63 ACE IL6
30 regulation of Cdc42 protein signal transduction GO:0032489 9.63 APOA1 APOE
31 reverse cholesterol transport GO:0043691 9.63 APOA1 APOE CETP
32 regulation of cholesterol transport GO:0032374 9.62 APOA1 APOE
33 negative regulation of plasminogen activation GO:0010757 9.61 CPB2 SERPINE1
34 very-low-density lipoprotein particle clearance GO:0034447 9.61 APOB APOE
35 lipoprotein catabolic process GO:0042159 9.59 APOB APOE
36 low-density lipoprotein particle remodeling GO:0034374 9.58 APOB APOE CETP
37 chylomicron assembly GO:0034378 9.54 APOA1 APOB APOE
38 very-low-density lipoprotein particle remodeling GO:0034372 9.5 APOA1 APOE CETP
39 chylomicron remodeling GO:0034371 9.43 APOA1 APOB APOE
40 cholesterol metabolic process GO:0008203 9.35 APOA1 APOB APOE CETP PON1
41 lipoprotein biosynthetic process GO:0042158 9.33 APOA1 APOB APOE
42 high-density lipoprotein particle remodeling GO:0034375 8.92 ALB APOA1 APOE CETP
43 lipid metabolic process GO:0006629 10.04 APOA1 APOB APOE CETP PON1

Molecular functions related to Coronary Stenosis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 lipid binding GO:0008289 9.62 ALB APOA1 APOE CETP
2 phospholipid binding GO:0005543 9.56 APOA1 APOB APOE PON1
3 cholesterol binding GO:0015485 9.54 APOA1 APOE CETP
4 carboxypeptidase activity GO:0004180 9.48 ACE CPB2
5 phospholipid transporter activity GO:0005548 9.46 APOA1 CETP
6 lipoprotein particle binding GO:0071813 9.43 APOA1 APOE
7 phosphatidylcholine-sterol O-acyltransferase activator activity GO:0060228 9.4 APOA1 APOE
8 low-density lipoprotein particle receptor binding GO:0050750 9.33 APOB APOE CRP
9 lipid transporter activity GO:0005319 9.26 APOA1 APOB APOE CETP
10 cholesterol transporter activity GO:0017127 8.92 APOA1 APOB APOE CETP

Sources for Coronary Stenosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
20 FMA
29 GO
30 GTR
31 HGMD
32 HMDB
33 HPO
34 ICD10
35 ICD10 via Orphanet
36 ICD9CM
37 IUPHAR
38 KEGG
39 LifeMap
41 LOVD
43 MedGen
45 MeSH
46 MESH via Orphanet
47 MGI
50 NCI
51 NCIt
52 NDF-RT
55 NINDS
56 Novoseek
58 OMIM
59 OMIM via Orphanet
63 PubMed
65 QIAGEN
70 SNOMED-CT via HPO
71 SNOMED-CT via Orphanet
72 TGDB
73 Tocris
74 UMLS
75 UMLS via Orphanet
Content
Loading form....